BR9916197A - Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral - Google Patents
Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebralInfo
- Publication number
- BR9916197A BR9916197A BR9916197-4A BR9916197A BR9916197A BR 9916197 A BR9916197 A BR 9916197A BR 9916197 A BR9916197 A BR 9916197A BR 9916197 A BR9916197 A BR 9916197A
- Authority
- BR
- Brazil
- Prior art keywords
- cerebral ischemia
- treatment
- erythropoietin
- derivatives
- brain tissue
- Prior art date
Links
- 201000006474 Brain Ischemia Diseases 0.000 title abstract 8
- 206010008120 Cerebral ischaemia Diseases 0.000 title abstract 8
- 206010008118 cerebral infarction Diseases 0.000 title abstract 8
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title abstract 6
- 102000003951 Erythropoietin Human genes 0.000 title abstract 5
- 108090000394 Erythropoietin Proteins 0.000 title abstract 5
- 229940105423 erythropoietin Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 210000005013 brain tissue Anatomy 0.000 abstract 2
- 208000006011 Stroke Diseases 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Patente de Invenção: <B>"MéTODO PARA O TRATAMENTO DE ISQUEMIA CEREBRAL E USO DE ERITROPOIETINA OU DERIVADOS DE ERITROPOIETINA PARA O TRATAMENTO DE ISQUEMIA CEREBRAL"<D>. A presente invenção refere-se a um método para o tratamento da isquemia cerebral e uma droga para o tratamento da isquemia cerebral em particular em humanos, como ocorre por exemplo no caso de pacientes com acidente vascular cerebral. Foi constatado surpreendentemente que a administração periférica de eritropoietina ao tecido cerebral afetado pela isquemia cerebral tem um efeito protetor distinto. A eritropoietina tem desse modo o efeito de que a região do tecido cerebral que é danificado permanentemente, em particular na penumbra, é dramaticamente reduzida relativa as medidas convencionais no caso da isquemia cerebral sem a administração da eritropoietina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19857609A DE19857609A1 (de) | 1998-12-14 | 1998-12-14 | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| PCT/EP1999/009864 WO2000035475A2 (de) | 1998-12-14 | 1999-12-13 | Verfahren zur behandlung von cerebralen ischämien sowie verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9916197A true BR9916197A (pt) | 2001-09-04 |
Family
ID=7891015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9916197-4A BR9916197A (pt) | 1998-12-14 | 1999-12-13 | Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US7514072B1 (pt) |
| EP (1) | EP1140139B2 (pt) |
| JP (2) | JP4750947B2 (pt) |
| KR (1) | KR100774827B1 (pt) |
| CN (1) | CN1187085C (pt) |
| AT (1) | ATE253932T1 (pt) |
| AU (1) | AU766216C (pt) |
| BG (1) | BG65417B1 (pt) |
| BR (1) | BR9916197A (pt) |
| CA (1) | CA2353553C (pt) |
| DE (2) | DE19857609A1 (pt) |
| DK (1) | DK1140139T4 (pt) |
| ES (1) | ES2211218T5 (pt) |
| HK (1) | HK1042655B (pt) |
| HU (1) | HUP0104709A3 (pt) |
| ID (1) | ID29107A (pt) |
| IL (2) | IL143579A0 (pt) |
| MX (1) | MXPA01005971A (pt) |
| NO (1) | NO330079B1 (pt) |
| NZ (1) | NZ541591A (pt) |
| PL (1) | PL202483B1 (pt) |
| PT (1) | PT1140139E (pt) |
| RO (1) | RO121409B1 (pt) |
| RU (1) | RU2242991C2 (pt) |
| WO (1) | WO2000035475A2 (pt) |
| ZA (1) | ZA200104626B (pt) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| US7410941B1 (en) | 1999-04-13 | 2008-08-12 | The Kenneth S. Warren Institute, Inc. | Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin |
| NZ545478A (en) * | 1999-04-13 | 2008-04-30 | Kenneth S Warren Inst Inc | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7345019B1 (en) | 1999-04-13 | 2008-03-18 | The Kenneth S. Warren Institute, Inc. | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US7078376B1 (en) | 2000-08-11 | 2006-07-18 | Baxter Healthcare S.A. | Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects |
| DE10043457A1 (de) * | 2000-09-04 | 2002-03-28 | Hannelore Ehrenreich | Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen |
| US7767643B2 (en) | 2000-12-29 | 2010-08-03 | The Kenneth S. Warren Institute, Inc. | Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| PA8536201A1 (es) * | 2000-12-29 | 2002-08-29 | Kenneth S Warren Inst Inc | Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina |
| US6531121B2 (en) | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
| US7048934B2 (en) | 2001-08-30 | 2006-05-23 | Stem Cell Therapeutics Inc. | Combined regulation of neural cell production |
| AR036401A1 (es) | 2001-09-14 | 2004-09-08 | Stem Cell Therapeutics Inc | Incremento de la cantidad de celulas madre neuronales inducido por prolactina. |
| DE10219545A1 (de) * | 2002-04-26 | 2003-11-06 | Lang Florian | Regulation der Apoptose |
| JP2005534650A (ja) * | 2002-06-11 | 2005-11-17 | ザ バーナム インスティテュート | エリスロポイエチンおよびインスリン様増殖因子の神経保護的相乗作用 |
| DE10234192B4 (de) | 2002-07-26 | 2009-11-26 | Epoplus Gmbh Co.Kg | Verwendung von Erythropoetin |
| MXPA05010345A (es) * | 2003-03-27 | 2006-03-08 | Johnson & Johnson | Uso de la eritropoyetina en la recuperacion del accidente cerebrovascular. |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| US20070111932A1 (en) * | 2003-07-31 | 2007-05-17 | Stem Cell Therapeutics Inc. | Method of enhancing and/or inducing neuronal migration using erythropoietin |
| WO2005032467A2 (en) | 2003-09-29 | 2005-04-14 | Warren Pharmaceuticals, Inc. | Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions |
| PT1675573E (pt) * | 2003-10-23 | 2008-12-30 | Otsuka Pharma Co Ltd | Formulação de iripiprazole injectável estéril de libertação controlada e um processo para a sua preparação |
| CA2556266A1 (en) | 2004-02-13 | 2005-08-25 | Stem Cell Therapeutics Corp. | Use of luteinizing hormone (lh), and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis |
| US9988427B2 (en) | 2005-05-13 | 2018-06-05 | Charite Universitaetsmedizen-Berlin | Erythropoietin variants |
| EP1736481A1 (en) | 2005-05-13 | 2006-12-27 | Charite Universitätsmedizin-Berlin | Erythropoietin variants |
| EP1933814A2 (en) * | 2005-09-15 | 2008-06-25 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
| EP1928488A4 (en) | 2005-09-27 | 2009-07-22 | Stem Cell Therapeutics Corp | REGULATION OF OLIGODENDROCYTE PRECURSOR CELL PROLIFERATION WITH PROLACTIN |
| EP2004211A4 (en) * | 2006-03-17 | 2010-07-07 | Stem Cell Therapeutics Corp | DOSEERSCHEMATA FOR LH OR HCG AND EPO FOR THE TREATMENT OF NEUROLOGICAL DISEASES |
| KR20090031547A (ko) * | 2006-06-07 | 2009-03-26 | 토쿠시마 대학 | 에리트로포이에틴을 이용한 허혈성 질환의 치료 |
| JP4879349B2 (ja) | 2007-07-31 | 2012-02-22 | 大塚製薬株式会社 | アリピプラゾール懸濁液及び凍結乾燥製剤の製造方法 |
| RU2446834C2 (ru) * | 2010-06-15 | 2012-04-10 | Елена Александровна Лебедева | Способ лечения пострадавших с сочетанной черепно-мозговой травмой |
| WO2012148200A2 (ko) | 2011-04-26 | 2012-11-01 | 아주대학교 산학협력단 | 허혈성 혈관 질환 치료시술 보조용 조성물 |
| RU2495688C1 (ru) * | 2012-03-28 | 2013-10-20 | Государственное бюджетное учреждение здравоохранения Центр организации специализированной медицинской помощи "Челябинский государственный институт лазерной хирургии" | Способ лечения ишемии головного мозга в эксперименте |
| US9610444B2 (en) | 2013-03-15 | 2017-04-04 | Pacesetter, Inc. | Erythropoeitin production by electrical stimulation |
| KR20190052855A (ko) | 2017-11-09 | 2019-05-17 | 대한제당 주식회사 | 페길레이션된 에리스로포이에틴을 포함하는 허혈성 뇌질환 치료용 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
| JPS6197229A (ja) | 1984-10-18 | 1986-05-15 | Chugai Pharmaceut Co Ltd | 安定なエリトロポエチン製剤 |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US5013718A (en) * | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| SG122763A1 (en) | 1989-11-06 | 2006-06-29 | Cell Genesys Inc | Production of proteins using homologous recombination |
| EP0505500B1 (en) | 1989-12-22 | 1997-07-30 | Applied Research Systems Ars Holding N.V. | Endogenous gene expression modification with regulatory element by way of homologous recombination |
| US5750376A (en) | 1991-07-08 | 1998-05-12 | Neurospheres Holdings Ltd. | In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| PT101031B (pt) | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| JP3537151B2 (ja) * | 1991-12-26 | 2004-06-14 | 中外製薬株式会社 | 脳機能障害による疾患の予防・治療薬 |
| RU2068268C1 (ru) * | 1992-03-19 | 1996-10-27 | Учебно-научный центр Медицинского центра при Правительстве РФ | Способ профилактики церебро-васкулярных заболеваний |
| US5614184A (en) | 1992-07-28 | 1997-03-25 | New England Deaconess Hospital | Recombinant human erythropoietin mutants and therapeutic methods employing them |
| US5661125A (en) | 1992-08-06 | 1997-08-26 | Amgen, Inc. | Stable and preserved erythropoietin compositions |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| AU697453B2 (en) | 1993-04-29 | 1998-10-08 | Abbott Laboratories | Erythropoietin analog compositions and methods |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| SE520730C2 (sv) | 1995-01-20 | 2003-08-19 | Eskil Elmer | Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel |
| US6121246A (en) | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
| US6165783A (en) | 1997-10-24 | 2000-12-26 | Neuro Spheres Holdings Ltd. | Erythropoietin-mediated neurogenesis |
| DE19857609A1 (de) | 1998-12-14 | 2000-06-15 | Hannelore Ehrenreich | Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen |
| NZ545478A (en) | 1999-04-13 | 2008-04-30 | Kenneth S Warren Inst Inc | Modulation of excitable tissue function by peripherally administered erythropoietin |
| US20030072737A1 (en) | 2000-12-29 | 2003-04-17 | Michael Brines | Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
-
1998
- 1998-12-14 DE DE19857609A patent/DE19857609A1/de not_active Ceased
-
1999
- 1999-12-13 WO PCT/EP1999/009864 patent/WO2000035475A2/de not_active Ceased
- 1999-12-13 DK DK99966958T patent/DK1140139T4/da active
- 1999-12-13 NZ NZ541591A patent/NZ541591A/en not_active IP Right Cessation
- 1999-12-13 CN CNB998160474A patent/CN1187085C/zh not_active Expired - Fee Related
- 1999-12-13 RO ROA200100684A patent/RO121409B1/ro unknown
- 1999-12-13 KR KR1020017007421A patent/KR100774827B1/ko not_active Expired - Fee Related
- 1999-12-13 AU AU22831/00A patent/AU766216C/en not_active Ceased
- 1999-12-13 CA CA2353553A patent/CA2353553C/en not_active Expired - Fee Related
- 1999-12-13 RU RU2001116077/14A patent/RU2242991C2/ru not_active IP Right Cessation
- 1999-12-13 HU HU0104709A patent/HUP0104709A3/hu unknown
- 1999-12-13 PT PT99966958T patent/PT1140139E/pt unknown
- 1999-12-13 PL PL349335A patent/PL202483B1/pl not_active IP Right Cessation
- 1999-12-13 US US09/868,089 patent/US7514072B1/en not_active Expired - Fee Related
- 1999-12-13 IL IL14357999A patent/IL143579A0/xx active IP Right Grant
- 1999-12-13 ID IDW00200101535A patent/ID29107A/id unknown
- 1999-12-13 AT AT99966958T patent/ATE253932T1/de active
- 1999-12-13 JP JP2000587794A patent/JP4750947B2/ja not_active Expired - Fee Related
- 1999-12-13 HK HK02104485.2A patent/HK1042655B/zh not_active IP Right Cessation
- 1999-12-13 MX MXPA01005971A patent/MXPA01005971A/es active IP Right Grant
- 1999-12-13 DE DE59907752T patent/DE59907752D1/de not_active Expired - Lifetime
- 1999-12-13 ES ES99966958T patent/ES2211218T5/es not_active Expired - Lifetime
- 1999-12-13 BR BR9916197-4A patent/BR9916197A/pt not_active Application Discontinuation
- 1999-12-13 EP EP99966958A patent/EP1140139B2/de not_active Expired - Lifetime
-
2001
- 2001-06-05 IL IL143579A patent/IL143579A/en not_active IP Right Cessation
- 2001-06-06 ZA ZA200104626A patent/ZA200104626B/en unknown
- 2001-06-07 BG BG105575A patent/BG65417B1/bg unknown
- 2001-06-12 NO NO20012896A patent/NO330079B1/no not_active IP Right Cessation
-
2010
- 2010-12-20 JP JP2010283105A patent/JP2011079860A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9916197A (pt) | Método para o tratamento de isquemia cerebral e uso de eritropoietina ou derivados de eritropoietina para o tratamento de isquemia cerebral | |
| BR0010113A (pt) | Preparações para uso externo na pele | |
| BR9913288A (pt) | Composição antioxidante compreendendo acetil l-carnitina e ácido alfa-lipóico | |
| BR0013540A (pt) | Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva | |
| BRPI0009956A (pt) | composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e betametasona, e, uso da mesma | |
| BR9912098A (pt) | Derivado de tiobenzimidazol, composição farmacêutica, e, agente preventivo e/ou terapêutico | |
| BR9815442A (pt) | Liberação terapêutica dirigida de compostos de vitamina d | |
| BR9408378A (pt) | Composto sal farmaceuticamente aceitável composição farmacêutica e processos para o tratamento de um paciente que sofreu um derrame e que sofre de uma condição de perda progressiva de função de sistema nervoso central e para melhorar os efeitos colaterais causados em um paciente por tratamento antineoplástico de doença que produz danos oxidativos | |
| BR9911072A (pt) | Preparações para aplicação de agentes antiinflamatórios, especialmente anti-sépicos e/ou agentes promotores da cura de feridas no trato respiratório inferior | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| BR0209523A (pt) | Utilização de um antioxidante para a fabricação de um medicamento destinado ao tratamento e/ou à prevenção dos distúrbios oculares de superfìcie | |
| BR9910553A (pt) | Composição de liberação prolongada, processo para produção da mesma, produto de liberação prolongada, formulação farmacêutica, e, processo para tratamento de uma indicação, de um distúrbio e uma inflamação | |
| BR0209658A (pt) | Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina | |
| BR0212576A (pt) | Método para o tratamento de distúrbios da pele | |
| BR0312845A (pt) | Tetratiomolibdato de tetrapropilamÈnio e compostos relacionados para terapias antiangiogênicas | |
| ES2157005T3 (es) | Uso del acido boswellico y sus derivados para la inhibicion de la actividad normal y elevada de la elastasa de leucocitos o de la plasmina. | |
| ES2153906T3 (es) | Uso de incienso para el tratamiento de la enfermedad de alzheimer. | |
| BRPI0408829A (pt) | uso de eritropoietina em recuperação de acidente vascular cerebral | |
| BR0309595A (pt) | Injeção produzida a partir de ixeris sonchifolia hance para o tratamento de doenças vasculares cardiocerebrais e doenças de fundo, e método para a produção da mesma | |
| BR0210744A (pt) | Combinação farmacêutica sinergìstica para a prevenção ou tratamento de diabetes | |
| BRPI0414139A (pt) | métodos e composições para tratar infecções por herpes | |
| BR9912703A (pt) | Composição antioxidante, antiprolìfera, compreendendo uma carnitina e um carotenóide | |
| BR9712614A (pt) | Composição farmacêutica,processos para aumentar e manter a homogeneidade de uma composição farmac&eutica,para tratar,reverter,reduzir ou inibir infeccões retrovirais e para preparação de uma composição farmacêutica,uso de lamivudina ou de um derivado farmaceuticamenete aceitável da mesma,de zidovudina,ou de um derivado farmaceuticamente aceitável da mesma e de um agente de deslizamento farmaceuticamente aceitável,e, artigo de amnufatura. | |
| BR0212167A (pt) | Forma de dosagem oral de liberação prolongada, uso da mesma, método para a prevenção e/ou tratamento de distúrbios e perturbações médicas, e, processo para a fabricação de uma forma de dosagem de liberação prolongada | |
| BR0009676A (pt) | Método para o tratamento e/ou profilaxia de malária, usos de atovaquona e de uma combinação de atovaquona, proguanila e primaquina, combinação de atovaquona, proguanila e primaquina, kit, e, formulação farmacêutica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 10 (VIII) E 13 DA LPI. |
|
| B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL. |